Pulmotect’s novel proprietary technology provides access to an estimated $50-100 billion infectious disease market by addressing significant unmet needs in the prevention of pneumonia (a leading cause of death worldwide) and other respiratory infections in broad and diverse patient populations (e.g. oncology, ICU, transplant, AIDS/HIV, elderly, seasonal flu, pandemics, bioterror, and others).
Pulmotect’s initial market focus is on the prevention of respiratory infections in immunocompromised patients, specifically high-risk leukemia patients receiving chemotherapy. Respiratory infections affect immunocompromised patients at an extremely high rate (as high as 30-40% in some populations). Leukemia patients alone spend nearly $1 billion annually in the US on prophylactics for respiratory infections, yet still acquire pneumonia at an alarming rate and have a 50% mortality once infected. Pulmotect has targeted this market based on their unmet clinical need and the well defined onset of the immunocompromised status.
Three major markets exist for this technology:
- Immunocompromised patients: Initial focus is centered on high-risk leukemia patients, where physicians are eager to conduct clinical trials. Additional immunocompromised patients include ICU, elderly, HIV and other cancer patients.
- Treating and preventing pneumonia: Current methods to treat the flu are inadequate. By locally stimulating the innate immune system in the respiratory system, the flu could be better prevented and treated. Additional government concerns deal with pandemic threats.
- Bioterror uses: First responders, military personnel and the US population could benefit from locally stimulating the immune system providing protection in seconds instead of weeks.
